»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Bosutinib CAS 380843-75-4 SKI-606 BOSUTINIB manufacturer

5th

Gold Index: 88356

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Bosutinib CAS 380843-75-4 SKI-606 BOSUTINIB

Bosutinib CAS 380843-75-4 SKI-606 BOSUTINIB 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: According to customer requi...
Brand: MOSINTER
Molecular Weight: 530.45
Densiy: 1.36
Boiling point: 649.7°C at 760 mmHg
Vapour pressure: 9.15E-17mmHg at 25°C
Production Capacity: 1 Ton/Year
Delivery Date: Within 7 days
Molecular Formula: C26H29Cl2N5O3
Melting point: 116-120 ºC
Specification: CP/USP/EP
Flashing point: 346.7°C

Bosutinib marketed under the trade name Bosulif) is a tyrosine kinase inhibitorundergoing research for use in the treatment of cancer

Bosutinib (CAS: 380843-75-4)


Item

Index

Molecular Formula

C26H29Cl2N5O3

Molecular Weight

530.45

Specification

CP/USP/EP

Content

≥99.0%

Bosutinib (rINN/USAN; codenamed SKI-606, marketed under the trade name Bosulif) is a tyrosine kinase inhibitorundergoing research for use in the treatment of cancer.  Originally synthesized by Wyeth, it is being developed byPfizer.

Medical uses

Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

Contraindications

Bosutinib only has two known absolute contraindications, which are: known hypersensitivity to bosutinib and liver impairment.

Interactions

Bosutinib is both a substrate and an inhibitor of P-glycoprotein (P-gp) and CYP3A4. Hence P-gp and CYP3A4 inhibitors may increase plasma levels of bosutinib. Likewise CYP3A4 inducers may reduce plasma concentrations of bosutinib. It may also alter the metabolism and uptake (into the GIT by means of its P-gp inhibitory effects) of other medicine that are substrates for P-gp and CYP3A4.

Carcinogenicity and mutagenicity

Animal studies using up to three-times the clinical exposure (in terms of AUC) to bosutinib have failed to demonstrate any carcinogenic effects.[8] Mutagenic and clastogenic effects were not detected in vitro.

Mechanism of action

It is an ATP-competitive Bcr-Abl tyrosine-kinase inhibitor with an additional inhibitory effect on SRc family kinases (including Src, Lyn and Hck). Bosutinib inhibited 16 of 18 imatinib-resistant forms of Bcr-Abl expressed in murine myeloid cell lines, but did not inhibit T315I and V299L mutant cells.

Quality issues

Some commercial stocks of bosutinib (from sources other than the Pfizer material used for clinical trials) have recently been found to have the incorrect chemical structure, calling the biological results obtained with them into doubt.


bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: